Disc Medicine (IRON) announced that the last participant has been randomized and dosed in the pivotal Phase 3 APOLLO trial of bitopertin in EPP. Originally planned as a 150-person study, the study was expanded to 183 participants due to patient and physician demand.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- FDA review process for accelerated approval narrows, less predictable, WSJ says
- Disc Medicine price target raised to $79 from $78 at Wells Fargo
- Disc Medicine Implements Restructuring Following FDA Response
- Disc Medicine price target lowered to $83 from $114 at Truist
- Disc Medicine price target raised to $111 from $110 at Stifel